Global Pharmaceutical Excipients Market Forecasts 2024 to 2029: Rise in Chronic Diseases and Increasing R&D to Boost Growth

Research and Markets

25 June 2024 at 5:01 am·4-min read

Company Logo

Global Pharmaceutical Excipients Market

Dublin, June 25, 2024 (GLOBE NEWSWIRE) -- The "Global Pharmaceutical Excipients Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering.

The global pharmaceutical excipients market is projected to witness a CAGR of 9.23% during the forecast period to reach a total market size of US$12.822 billion by 2029, increasing from US$6.917 billion in 2022.

A few pharmaceutical dosage forms that are easily and widely available and utilized globally are tablets, capsules, topical creams and gels, implants, oral dosage, eye drops, injectable products, inhalers, transdermal patches, lozenges, and suppositories. Pharmaceutical excipients are utilized in these pharmaceutical medication formulations to help the processing, providing bulk or volume to API, and securing, supporting, or incrementing the stability of the dosage forms in the final product.

Increasing research and development (R&D) is expected to boost the pharmaceutical excipients market.

Expanded investigations and advancements in pharmaceutical formulations utilize multi-functional excipients to progress the process of production and medication quality. Excipients play a significant part in helping pharmaceutical manufacturers in giving progress persistent bolster by improving compliance and treatment viability.

The pharmaceutical industry's rising attention on R&D is anticipated to emphatically affect the industry for pharmaceutical excipients. These inert substances improve medicate steadiness and solvency and help in medicate delivery forms. They play a vital part in medication advancement, influencing the bioavailability, discharge profile, and solidness of dynamic drugs. R&D endeavors drive advancement in pharmaceutical medication details, with progressed sedate conveyance frameworks such as nanoparticles and liposomes frequently requiring specialized excipients.

Administrative bodies just like the FDA and EMA continuously upgrade regulations standard guidelines and benchmarks for pharmaceutical items, driving the requirement for excipients that meet the most recent measures. Customization of medication formulations on the basis of particular patient needs and restorative zones are significant. As pharmaceutical companies contribute to R&D all-inclusive, the request for pharmaceutical excipients is likely to extend around the world, with producers seeing expanded openings to supply to broader regions in the years ahead.

A rise in chronic diseases is expected to surge the pharmaceutical excipients market growth.

The rising generics medicine industry is driven by the rise in chronic illnesses and the improvement of excipients, which are a key figure within the pharmaceutical market growth. The rise in major chronic disorders, like cardiovascular, diabetes, cancer, and chronic respiratory conditions, is fueling the demand for different treatment alternatives.

Pharmaceutical companies are creating innovative medication formulations for fulfilling the requirement as well as emerging delivery frameworks to progress adequacy and effectiveness with the comfort and compliance of patients. These medicines frequently include complex regimens, requiring pharmaceutical excipients to improve the stability of the medicine, control release rates of the drug, and enhance its bioavailability. Specialized drug delivery systems are necessary for sustained release, targeted delivery to specific tissues, and overcoming solubility and absorption issues.

Pharmaceutical excipients can also be used to create patient-friendly dosage forms, such as extended-release tablets or convenient oral formulations. Innovations in therapeutic approaches, such as personalized medicine and biologics, often require specialized excipients for stability and effectiveness. Government initiatives and healthcare policies aimed at improving access to effective treatments for chronic diseases may contribute to the pharmaceutical excipient market growth.

Market Restraints:

Cost and time consumed in creating new excipients could hinder the market growth.

Pharmaceutical Excipients require mandatory inspections by the regulatory authorities of the manufacturing site. The industry lacks separate guidelines for approval and manufacturing of excipients is impending R&D initiatives related to excipients. If a new drug approval fails, the excipient also fails, even if it is not related to the excipient. Moreover, a considerable amount of time and cost goes into creating an excipient.

Key Attributes:

Report Attribute	Details
No. of Pages	126
Forecast Period	2022 - 2029
Estimated Market Value (USD) in 2022	$6.92 Billion
Forecasted Market Value (USD) by 2029	$12.82 Billion
Compound Annual Growth Rate	9.2%
Regions Covered	Global

Companies Featured

Ashland Global Holdings
DuPont
BASF SE
Roquette Feres
Evonik Industries AG
Croda International
Associated British Foods
Archer Daniels Midland Company
Lubrizol Corporation

Key Segmentation:

By Excipient Type

Polymers
Alcohols
Sugars
Minerals
Others

By Formulation Type

Oral
Topical
Parenteral
Others

By Functionality

Coating Agents
Flavoring Agents & Sweeteners
Lubricants & Glidants
Colorants
Emulsifying Agents
Buffering Agents
Others

By Distribution Channel

Online
Offline

By Geography

North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
Australia
Japan
South Korea
India
Thailand
Taiwan
Indonesia
Others

For more information about this report visit https://www.researchandmarkets.com/r/w8woc4

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

Global Pharmaceutical Excipients Market

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

The Telegraph
BT threatens to cut off broadband rivals over ‘lazy’ engineers
BT has threatened to shut broadband rivals out of its network amid a crackdown on “lazy” engineers failing to fill in crucial forms.
Evening Standard
Investigation after Ryanair Boeing 737 Max plunges 2,000ft in 17 seconds during flight to London Stansted
An investigation was launched after a Boeing 737 Max flown by Ryanair plunged at alarming speed during its final approach to London Stansted Airport, it has emerged.Flight data reveals that on December 4 last year, flight FR1269 dropped more than 2,000ft in a mere 17 seconds.
The Telegraph
How Putin handed America the keys to the world’s energy market
It did not take long for Vladimir Putin’s invasion of Ukraine to reshape the world’s energy markets, as countries long reliant on Russian gas sought to sever ties as soon as possible.
The Telegraph
The North Sea could be finished under Labour
David Latin is losing his patience. The chairman of Serica Energy has worked in the oil and gas industry for more than 30 years. He once ran a company that drilled in a war zone.
The Telegraph
Western incompetence is handing aerospace dominance to China
Regulators have concluded Boeing should face criminal charges over safety issues on the 737. It is being sued over a mid-air blowout. And design faults have left a pair of astronauts stranded in space.
Manchester Evening News
UK holidaymakers face more chaos as hotel agent cancels all July bookings
Tour operators say they are trying to source alternatives after the announcement by Youtravel
Ideal Home
En-suite ideas to design the perfect bathroom retreat
These en-suite ideas will help you bring a touch of luxury to your bedroom, and can also value to your home. In this private space, you can have free rein to go bold and be more adventurous with the bathroom – bright colours, intricate patterns, and beautiful finishes all have a place. ‘Also an en-suite is generally only used by adults, it also won’t have the same wear and tear that a family bathroom would have, so it makes sense to be the place where you invest in high-end fixtures and fittings,' says Barrie Cutchie, Design Director at BC Designs.
Business Insider
A millennial making $350,000 a year through overemployment says he only worked 50 hours a week
A Texas-based millennial who's making $350,000 secretly working two remote jobs says he only worked 50 hours a week.
Reuters
Top US carriers say roaming customers facing connectivity issues
In statements to Reuters, Verizon, AT&T and T-Mobile US said they were working to resolve the issue but did not provide details on the extent of the outage or the services partner responsible for it. However, a person familiar with the matter said it was due to a glitch at Syniverse, a telecom services firm that works with global carriers to support international roaming. In a response to Reuters, Syniverse said its systems were facing "intermittent connectivity issues" and was working with its network partners to fix the problem.
Reuters Videos
Aircraft delivery delays 'brutal' - Lufthansa CEO
STORY: Aircraft delivery issues are having a "brutal" impact on Lufthansa, and won't be resolved before the end of the decade.That's according to CEO Carsten Spohr, speaking at a business press club in Stuttgart late Thursday (June 27).He said the aircraft shortage could be costing Lufthansa some $535 million a year - although he did not provide an exact figure.The German group has ordered 250 new aircraft from Airbus and Boeing to modernize its fleet.Those deliveries are scheduled between this year and 2029, but Spohr said, "no plane arrives on time." He added around 100 of Lufthansa's 750 aircraft were grounded either for maintenance reasons or because they'd been decommissioned.Earlier this week, Airbus lowered its forecast for deliveries this year to around 770 jets from around 800. The announcement came with growing doubts among suppliers over its jet output as Airbus grapples with parts shortages.At rival Boeing, a series of incidents have raised regulatory scrutiny of the U.S. manufacturer.It's added to delays in deliveries that originated during the pandemic.
Reuters
Aramco close to agreeing 10% stake in Renault, Geely thermal engines JV, sources say
PARIS (Reuters) -Saudi Aramco is set to take a 10% stake in a thermal engine joint venture between Renault and China's Geely called Horse Powertrain, said two sources familiar with the matter, beefing up a business supplying legacy automakers as electric-vehicle sales slow. The agreement to take a 10% stake in the Horse Powertrain business, first reported by Bloomberg, is lower than the stake of around 20% which was cited by sources at the beginning of discussions. The transaction would value Horse Powertrain at around 7.4 billion euros ($7.92 billion), said one of the sources.
Bloomberg
German Businesses in India Say Bureaucratic Hurdles Worsening
(Bloomberg) -- More German companies cited bureaucratic hurdles in India as a problem to doing business in the country this year than in 2023, an issue that will likely feature in talks when Chancellor Olaf Scholz visits the South Asian nation later this year.Most Read from BloombergGavin Newsom Is Ready for the Biden EmergencyPanicked Emails, Gallows Humor: The Aftermath of Biden's Debate DisasterThe Question on Democrats’ Minds: How to Replace Biden?Biden’s Disastrous Debate Accelerates Doubts
Yahoo Finance Video
How Medicare drug price negotiations could hit pharma stocks
As a string of negative headlines and promising new developments present ideal buying opportunities for investors, Josh Lipton and Julie Hyman perform a mid-year check on the pharmaceutical industry. Goldman Sachs senior biotechnology analyst Chris Shibutani joins Market Domination to break down the health of the pharmaceutical large-caps and unrecognized areas of opportunity in the sector.  Shibutani says the industry is "quite healthy," but acknowledges there are always "cross currents." He points to "tremendous advancements" in biotechnology innovation rising to daunting unmet needs, from cancer to cardiovascular disease. The analyst points to "holy grail-like" opportunities such as obesity drugs, and notes improvements in chemotherapy and next-generation antibody-drug conjugates for cancer treatment. However, Shibutani explains that the Inflation Reduction Act may challenge the industry, as the landmark legislation stipulates drug price negotiation for Medicare that is "beginning to play out." For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This article was written by Gabriel Roy
The Telegraph
Retail sales plunge in blow for German economy
Retail sales are plunging in Germany in a fresh blow to chancellor Olaf Scholz’s hopes of an economic recovery.
Reuters
US Supreme Court blocks Purdue Pharma bankruptcy settlement
WASHINGTON (Reuters) -The U.S. Supreme Court on Thursday blocked OxyContin maker Purdue Pharma's bankruptcy settlement that would have shielded its wealthy Sackler family owners from lawsuits over their role in the nation's deadly opioid epidemic. The 5-4 decision reversed a lower court's ruling that had upheld the plan to give Purdue's owners immunity in exchange for paying up to $6 billion to settle thousands of lawsuits accusing the company of unlawful misleading marketing of OxyContin, a powerful pain medication introduced in 1996. The ruling represented a victory for President Joe Biden's administration, which had challenged the settlement as an abuse of bankruptcy protections meant for debtors in financial distress, not people like the Sacklers who have not filed for bankruptcy.
TechCrunch
Feather raises €6M to go Pan-European with its insurance platform for expats
As a foreigner, navigating health insurance systems can often be difficult. German startup Feather thinks it has a solution and raised €6 million to help some of the 40-plus million expats working and living in Europe. It is not that there are no options for foreign nationals to get insurance; there are plenty.
Investing.com
Oil prices settle higher on supply disruption jitters amid geopolitical tensions
Investing.com -- Oil prices settled higher Thursday as rising Middle East tensions stoked worries about global supplies disruptions, overshadowing data from a day earlier showing a surprise build in U.S. inventories.
Yahoo Finance Video
Is it time to sell your business? Postmates founder explains
Tiptop Founder and CEO Bastian Lehmann — also the founder and CEO of Postmates — joins Wealth! to give insight into how to tell if it is time to sell your business: "It's probably, a good idea to just focus on building a lasting company. And what happens is that potential buyers will ultimately notice that and you can get extra credit for building something that ultimately becomes inevitable. And someone has to buy your business. I think that's always a very strong position to be in," says Lehmann For more expert insight and the latest market action, click here to watch this full episode of Wealth! This post was written by Nicholas Jacobino
Sky News
Labour's North Sea oil and gas policy under attack from industry and activists
One of the policy areas on which the Labour Party has been very specific during this general election campaign is its approach towards North Sea oil and gas production. The party has been clear that it will raise existing windfall taxes first slapped on North Sea oil and gas producers in 2022 by Rishi Sunak, when he was chancellor, taking the total level of tax from the current 75% to 78%. Ed Miliband, the shadow secretary of state for energy security and net zero, also proposes to take away tax reliefs Mr Sunak put in place alongside the windfall tax, to sugar the pill, which allowed producers to offset their investments in new production against their tax bills.
Bloomberg
The List of Money Managers Axing Oil Stocks Just Got Longer
(Bloomberg) -- There’s a growing list of institutional investors in Europe who are stripping oil and gas stocks out of their portfolios, in a move they say reduces the risk of ending up with stranded assets and financial losses.Most Read from BloombergGavin Newsom Is Ready for the Biden EmergencyThe Question on Democrats’ Minds: How to Replace Biden?Biden’s Disastrous Debate Accelerates Doubts Over CandidacySupreme Court Overturns Chevron Rule in Blow to Agency Power‘I Was Afraid of This’: Biden

FTSE 100

FTSE 250

AIM

GBP/EUR

GBP/USD

Bitcoin GBP

CMC Crypto 200

S&P 500

DOW

CRUDE OIL

GOLD FUTURES

NIKKEI 225

HANG SENG

DAX

CAC 40

8 UK holiday home businesses you could buy now

Global Pharmaceutical Excipients Market Forecasts 2024 to 2029: Rise in Chronic Diseases and Increasing R&D to Boost Growth

Latest stories

BT threatens to cut off broadband rivals over ‘lazy’ engineers

Investigation after Ryanair Boeing 737 Max plunges 2,000ft in 17 seconds during flight to London Stansted

How Putin handed America the keys to the world’s energy market

The North Sea could be finished under Labour

Western incompetence is handing aerospace dominance to China

UK holidaymakers face more chaos as hotel agent cancels all July bookings

En-suite ideas to design the perfect bathroom retreat

A millennial making $350,000 a year through overemployment says he only worked 50 hours a week

Top US carriers say roaming customers facing connectivity issues

Aircraft delivery delays 'brutal' - Lufthansa CEO

Aramco close to agreeing 10% stake in Renault, Geely thermal engines JV, sources say

German Businesses in India Say Bureaucratic Hurdles Worsening

How Medicare drug price negotiations could hit pharma stocks

Retail sales plunge in blow for German economy

US Supreme Court blocks Purdue Pharma bankruptcy settlement

Feather raises €6M to go Pan-European with its insurance platform for expats

Oil prices settle higher on supply disruption jitters amid geopolitical tensions

Is it time to sell your business? Postmates founder explains

Labour's North Sea oil and gas policy under attack from industry and activists

The List of Money Managers Axing Oil Stocks Just Got Longer